Skip to Main Content
Welcome to the Scientist.com Marketplace

Go to Main Navigation

ClinicaGen Bio LLC

Start a request
Year Established:
2022
Website:
clinicagenbio.com
Headquarters:
Manvel, TX, US
Company Type:
New Startup (0-1M TTM Revenue)
Open Requests:
2

ClinicaGen Bio LLC is a clinician-founded network of multispecialty practices dedicated to biospecimen research including custom prospective collection, scheduled diagnostic remnant retention and prototype R/D in-vitro diagnostic instrument hosting. We have taken the regulatory burden off the client by designing a unique biospecimen collection protocol with ICFs and waiver of informed consent for diagnostic remnants which all have current IRB approval. We have experienced clinical source facilities in 9 states ready to fulfill your collection request in Gynecology, Neurology, Psychiatry, Pulmonology, Internal/Family Medicine, Pediatrics, Dermatology, Podiatry, Cardiology, Endocrinology, Infections Disease/Immunology, Pain Management, or Ophthalmology. Our services are specific to fresh collections and do not include banked samples at this time.

We also offer consulting services to industry and researchers which highlight US clinical operations as it relates to biospecimen collections to provide insight into timelines, patient populations, insurance considerations and other factors that influence studies.

Site Badges
ClinicaGen Bio, LLC
6811 Hawkins St Manvel, TX, 77578 United States

Get started

If your organization has a Scientist.com marketplace, you can log in here to order products and services directly.

If you're interested in ordering custom research services from suppliers in the Scientist.com network, book a meeting with our team here.

To order products instantly, request access below.

Password must:

• Be at least 12 characters in length

• Contain a lowercase letter (a-z)

• Contain an uppercase letter (A-Z)

• Contain a numeral (0-9)

• Contain a special character (%, $, !, @)

By signing up for this account you agree to the Terms of Service